Page 21234..1020..»

Category Archives: Psychedelics

U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD – New Santa Ana

Posted: January 5, 2024 at 6:32 pm

ORANGE COUNTY, Calif. Today, following the Department of Veterans Affairs (VA) issuing a request for applications (RFA) for proposals from its network of VA researchers to study the use of certain psychedelic compounds in treating posttraumatic stress disorder (PTSD) and depression,Representatives Lou Correa (CA-46)andJack Bergman (MI-01), co-chairs of thePsychedelics Advancing Therapies (PATH) Caucus, released the below statement:

To say this moment is monumental would be an understatement. Weve been fighting for years to push the VA to research the impact of breakthrough therapies, like psychedelics, on the invisible wounds of our countrys most valiant warriorswith the House passing our amendment to do just that last year,Correa said.These therapies promise to be one of the largest breakthroughs in mental health treatment in nearly half a century, and, with some reported signs of up to 80% success in treatment, shows a possibility to cure our veterans of their invisible woundsand be the first step toward tackling our national mental health crisis head-on. I could not be more proud to have been in this fight alongside General Bergman to get to this point, and we wont stop until these potentially life-saving therapies are accessible to all who would benefit from them.

Last year, the House of Representatives passed theCorrea-Bergman Amendment, which wasincluded in federal funding legislation, to push the U.S. Department of Veterans Affairs (VA) to carry out large-scale studies into drugs like psilocybin and MDMAwhich have been designated as breakthrough therapies by the Food and Drug Administration (FDA).

If psychedelic-assisted therapy can help treat a servicemember or Veterans PTSD, or prevent them from taking their own life, then we owe it to them to take an active role in researching these potentially life-saving therapies,Bergman said.Im grateful for Secretary McDonoughs commitment to making VA a leader in this promising new field of research, and for my friend Lou Correas work and leadership to help move this forward. This is the next first stepand I will continue fighting to advance these promising therapies that could save the lives of countless Veterans.

The Correa-Bergman Amendmentamended the Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill. It encouraged the VA to explore utilizing federal dollars to fund research into the impact of breakthrough therapies, including psychedelics, on veterans who return home from combat with invisible wounds. It passed by unanimous consent, and was included in the final text of the Military Construction, Veterans Affairs, and Related Agencies Appropriations Bill, which passed out of the House last year. You can find the full text of the amendmentHERE.

CorreaandBergmanare Co-Chairs of Congressional Psychedelics Advancing Therapies (PATH) Caucus, where theypromoterigorous and urgent clinical research into the efficacy of psychedelics in treating brain health conditions, in accordance with the law.

Congressman Lou Correa is a longtime Orange County resident, with deep local roots. To this day, he lives only three miles from his childhood neighborhood in Anaheim. He is the son of working-class parents whose hard work gave him a chance at success, and has spent his career fighting to protect the American Dream, and ensure anyone can reach the middle class, just as he did. In 2016, Lou was elected to the U.S. House of Representatives to continue his work by representing the community he has spent the past 20 years serving, fighting to give everyone access to the same opportunity he had. Congressman Correa is committed to working across party lines to strengthen the middle class and give everyone a shot at the American Dream by investing in education, healthcare, and our fading infrastructure, and has introduced legislation to protect the legal rights of immigrants, care for veterans, and fight against the wasteful spending of taxpayer money.

Like Loading...

Read the original here:

U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana

Posted in Psychedelics | Comments Off on U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD – New Santa Ana

DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination – Marijuana Moment

Posted: at 6:31 pm

A top Drug Enforcement Administration (DEA) has affirmed that spores that produce so-called magic mushrooms are not, on their own, federally prohibited.

DEAs Drug & Chemical Evaluation Section Chief Terrence Boos was asked about the legal status of the spores in a letter from attorney Michael McGuire in November, and he sent a response on Tuesday that clarified the agencys position.

If the mushroom spores (or any other material) do not contain psilocybin or psilocin (or any other controlled substance or listed chemical), the material is considered not controlled under the Controlled Substances Act (CSA), Boos wrote.

However, if at any time the material contains a controlled substance such as psilocybin or psilocin (for example, upon germination), the material would be considered a controlled substance under the CSA, he said, as Kight On Cannabis first reported.

This isnt especially revelatory, as its long been understood that the CSA doesnt explicitly ban spores that can be used to produce so-called magic mushrooms. Rather, it lists the key psychoactive ingredients in psychedelic mushrooms, psilocybin and psilocyn, as Schedule I controlled substances.

Because the spores themselves dont contain those specific compounds, they are uncontrolled under the CSA.

However, it should be noted that while the spores are technically considered federally legalas long as someone doesnt use them to produce mushrooms that contain psilocybin or psilocinstates such as California, Georgia and Idaho do prohibit the spores themselves.

The DEA letter still marks an important clarification, though. As attorney Rod Kight pointed out, police have still arrested people for selling or utilizing spore kits. But its possible that could be connected to a different question of whether the kits are considered drug paraphernalia, which may depend on how spore kits are marketed or used, he wrote.

In short, this newest DEA letter is a positive clarification of a long-debated issue. However, it does not necessarily open the doors to widespread use and sale of spore kits, Kight said. At a minimum, buyers and sellers should understand the legal issues with a lawyer, and act accordingly.

The spore versus mushroom question mirrors another DEA paradox that was addressed in separate, earlier letters from Boos: while marijuana is federally prohibited, the seeds that produce that plant are not (as long as they do not contain more than 0.3 percent THC by dry weight).

If the seeds fall under that threshold, they are considered federally legal hemp, under the definition set out in the 2018 Farm Bill that legalized the non-intoxicating crop. Boos made that distinction in a letter to attorney Shane Pennington in January 2022.

Meanwhile, the DEA official issued another relevant administrative interpretation of cannabis statute last year when he asserted that the agency considers the intoxicating cannabinoid delta-8 THC an illicit Schedule I drug if its synthesized from federally legal CBD.

Delta-8 THC products have proliferated on the market since hemps legalization, essentially existing in an unregulated legal grey area. If the cannabinoid is naturally extracted from hemp, its federally legal. But its generally considered common practice to synthesize it from CBD because its a more cost-effective process. Some states have taken steps to restrict delta-8 THC, however.

At DEAs 2023 Supply Chain Conference in May, Boos similarly explained that synthetic cannabinoids are banned, and he said that DEA is in the process of developing a final rule to formally clarify that policy, at the recommendation of the U.S. Department of Health and Human Services (HHS).

Boos also told a lawyer last year that the minor cannabinoids delta-8 THC-0 and delta-9 THC-O are prohibitedbecause they can only be synthetically produced.

Some experts have disputed DEAs interpretation of the statute on intoxicating hemp-based cannabinoids, however. And a federal appeals court ruled in 2022 that the way that existing rules are written makes delta-8 THC exempt from control, as the law is silent on the minor cannabinoid while clearly legalizing hemp extracts and derivatives.

The letter of psychedelic mushroom spores comes after a federal appellate panel denied a motion by lawyers for a Washington State doctor trying to reschedule psilocybinunder the CSA. In an order last month, a three-judge panel of the U.S. Court of Appeals for the Ninth Circuit rejected the doctors request for a rehearing of an earlier court decision that returned the matter to DEA.

DEA recently announced that it is taking another shot atbanning two psychedelics after abandoning its original scheduling proposal in 2022, teeing up another fight with researchers and advocates who say the compounds hold therapeutic potential.

The agency separatelybacked down from a proposal to ban five different tryptamine psychedelics in 2022amid sizable pushback from the research and advocacy communities.

DEA is also warning Georgia pharmacies that dispensing THC is unlawfulbecause it remains a Schedule I drug after the state became the first in the U.S. to allow pharmacies to sell medical marijuana, with nearly 120 facilities applying to sell cannabis oil.

Its additionallycalling for the production of even more THC, psilocybin and DMT for research purposes than it initially proposed for 2024raising its quotas for those drugs whilemaintaining already high production goals for marijuana and other psychedelics.

Meanwhile, DEA is actively conducting a review into marijuana scheduling after receiving a recommendation from HHS to move it from Schedule I to Schedule III under the CSA. The agency said in a letter to Congress last month that it reserves the final authority to make any scheduling decision on cannabis, regardless of what the HHS recommends.

Read the full DEA letter on psilocybin mushroom spores below:

New Kentucky Bill Would Legalize Marijuana Use, Possession And Home CultivationBut Not Sales

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Original post:

DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment

Posted in Psychedelics | Comments Off on DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination – Marijuana Moment

Psychedelics for Psych Conditions Made Their Mark in 2023 – Medpage Today

Posted: at 6:31 pm

In January, we reported on an investigational psychedelic that alleviated symptoms of depression in a mid-stage trial. In this report, we follow up on what has happened since that study was published.

In the phase IIa trial, an investigational N,N-dimethyltryptamine treatment -- commonly known as the hallucinogen DMT -- significantly reduced depressive symptoms by 7.4 points more than placebo (P=0.02) at 2 weeks after treatment when using the Montgomery-Asberg Depression Rating Scale (MADRS).

The antidepressant effects were seen within just a week after a 21.5-mg infusion of the agent, dubbed SPL026, was administered with supportive therapy.

Since this trial, several other psychedelics have made their way down the developmental pipeline, showing a wide range of psychiatric therapeutic effects.

The Magic of Magic Mushrooms

In August, another phase II trial showed that just a single dose of psilocybin significantly improved depression symptoms and functional disability in patients with major depressive disorder. Here, a 25-mg dose of synthetic psilocybin -- found in Psilocybe mushrooms, commonly known as "magic mushrooms" -- resulted in a sustained 12.3-point (95% CI -17.5 to -7.2) greater improvement versus active niacin placebo in MADRS score on day 43.

With this treatment, which was co-administered with psychological support, patients had a significant improvement in symptoms as early as the second day.

Of note, psilocybin didn't just work well for major depressive disorder. In July, the same single synthetic dose of the psychedelic was found to be safe and tolerable in a phase I study of women with anorexia. Only 10 women were enrolled in the early-stage trial, which reported significant improvements in psychopathology, but no changes in body mass index.

Later in the year, psilocybin eased symptoms of treatment-resistant bipolar depression in a trial of 15 people. MADRS scores decreased by 24 points at 3 weeks in participants with bipolar type II disorder, and 11 patients even met remission criteria.

"Psychedelics have the potential to ease the suffering of many patients with difficult-to-treat mood disorders, and some folks with a cyclical mood disorder could benefit," study author Scott T. Aaronson, MD, of the Sheppard Pratt Health System in Baltimore, told MedPage Today in early December.

Other trials this year also highlighted psilocybin's therapeutic effects on treatment-resistant depression -- with or without the aid of traditional antidepressants -- and depression for patients with cancer.

MDMA, Ketamine Gain More Traction

In September, positive findings from a late-stage trial highlighted MDMA's therapeutic effects on post-traumatic stress disorder (PTSD) symptoms. Building on phase II findings released in 2021, adding MDMA pharmacotherapy to psychotherapy significantly improved PTSD symptoms compared with placebo with psychotherapy (least squares mean change -23.7 vs -14.8). The compound, which was granted a breakthrough therapy designation in 2017, also significantly improved clinician-rated functional impairment in a diverse patient population.

"The hope is that MDMA and psychedelics in general might have a signal in not just PTSD and depression ... but in other mental health disorders as well," study author Jennifer M. Mitchell, PhD, of the University of California San Francisco, told MedPage Today in the fall. "The objective will be to evaluate all of the psychedelics in each of these different disorders to determine how far the therapeutic efficacy reaches."

Because of the successes observed in phase II and III trials, MAPS Public Benefit Corporation announced in mid-December that it submitted a new drug application to the FDA asking for priority review. If approved, the Drug Enforcement Administration would be required to reschedule MDMA, making it available for prescription medical use, the developer said.

While not a classic psychedelic in the traditional sense, ketamine also continued to prove its therapeutic benefits throughout 2023. According to a major study published in May, ketamine worked just as well as electroconvulsive therapy -- the "gold standard" for treatment-resistant depression. Following a 3-week treatment period, 55.4% of the patients in the ketamine group and 41.2% of those in the electroconvulsive therapy group had a treatment response, a 14.2% difference (95% CI 3.9-24.2).

In IV form, ketamine is only FDA approved as a sedative, analgesic, and general anesthetic. Esketamine (Spravato) nasal spray is approved alongside an oral antidepressant for treatment-resistant depression.

"Ketamine's effectiveness, in the aggregate results, looks a bit better than electroconvulsive therapy for major depression not associated with psychotic features," lead investigator Amit Anand, MD, director of Psychiatry Translational Clinical Trials at Mass General Brigham in Boston, told us at the American Psychiatric Association annual meeting.

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, shes worked at the company since 2015.

More here:

Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today

Posted in Psychedelics | Comments Off on Psychedelics for Psych Conditions Made Their Mark in 2023 – Medpage Today

2023: A Good Trip Around the Sun for Psychedelics – The National Law Review

Posted: at 6:31 pm

2023: A Good Trip Around the Sun for Psychedelics  The National Law Review

Read more from the original source:

2023: A Good Trip Around the Sun for Psychedelics - The National Law Review

Posted in Psychedelics | Comments Off on 2023: A Good Trip Around the Sun for Psychedelics – The National Law Review

Understanding the Role of the FDA in Advancing Psychedelic Therapy – Medriva

Posted: at 6:31 pm

Understanding the Role of the FDA

The U.S. Food and Drug Administration (FDA), a division of the Department of Health and Human Services, is entrusted with safeguarding public health. This involves ensuring the safety, effectiveness, and security of a wide range of products, including drugs, vaccines, medical devices, food supply, cosmetics, dietary supplements, and tobacco products. Among the many areas under its purview, the FDA also oversees the regulatory aspects of psychedelic clinical trials, and the current research in this area is gaining momentum.

In a bid to advance the field of psychedelic research, the FDA has announced a two-day virtual public workshop titled Advancing Psychedelic Clinical Study Design in collaboration with the Reagan-Udall Foundation. The workshop aims to gather researchers, regulated industry representatives, and other stakeholders to discuss scientific issues related to working with psychedelics in clinical trials and drug development. The FDA issued its first draft psychedelics guidance for the industry in June 2023, offering general considerations to sponsors developing psychedelic drugs for the treatment of medical conditions.

Research into the therapeutic benefits of psychedelic drugs dates back 80 years. However, government regulations have long hindered progress in this field. In recent years, there has been a resurgence of interest in the benefits of psychedelic medicines, leading to clinical trials for treating conditions like treatment-resistant depression and PTSD. The FDAs new draft guidance for researchers investigating the use of psychedelic drugs for potential medical treatment signals a promising pathway to approval. Despite the logistical challenges of conducting clinical research and ensuring patient safety, there is a potential move towards refining the therapeutic benefits of these drugs while minimizing their psychedelic effects.

The American Medical Association has set new standards for assigning specific codes to psychedelic therapies for data collection on novel treatments. In July, the AMA approved Current Procedural Terminology (CPT) III codes for psychedelic medicines, facilitating health providers in seeking coverage and reimbursement for these treatments. Alongside this, the FDA is considering an application to approve MDMA as a prescription drug, with MAPS PBC requesting an expedited six-month review instead of the standard 10-month review. If approved, it would mark a historic moment, making MDMA the first psychedelic to be approved as a pharmaceutical to be administered with psychotherapy and other supportive services.

The FDAs draft guidance for researchers interested in developing psychedelic drugs for the treatment of medical conditions has sparked optimism in medical communities. This shift in attitude is seen against the backdrop of the historical context of psychedelics, the Controlled Substance Act, and the resurgence of research funding for psychedelics. Notably, the FDA has already approved esketamine for the treatment of depression in adults, paving the way for further research and harnessing the potential therapeutic benefits of psychedelic drugs.

Read more:

Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva

Posted in Psychedelics | Comments Off on Understanding the Role of the FDA in Advancing Psychedelic Therapy – Medriva

MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics – Psychedelic Alpha

Posted: at 6:31 pm

Amy, Henry and Protik then took to the stage, with Emerson kicking off a fireside-type discussion with the Helena executives.

But why had Helena, which has invested in grid-scale energy storage and carbon-negative diamonds, become so interested in psychedelics?

The shit works, Elkus responded when asked what drew him into the space. The data on this is so incredibly compelling, it kind of doesnt even require using stage time to talk about it.

In what followed, Elkus echoed Doblins assessment of todays crisis state of humanity and talked of a present real risk moment for human civilisation, adding that you cannot solve any problem without, as a prerequisite, human coordination [], human empathy.

In MAPS PBC and psychedelics (drug development) more broadly, then, Elkus sees a dual benefit.

MDMA-assisted therapy, for example, represents something that in the here and now works, but also something that in the medium- and long-term, if we introduce these concepts to civilisation, could kind of end the model of accumulation without empathy or without distribution. Thats what I think psychedelics can allow for the rest of the 21st century, Elkus said.

And so to have an opportunity to work on both of those at the same time, especially without them cannibalising each other, is a once in a lifetime opportunity, he said, and were just glad to be here.

Helena was founded by Elkus, who dropped out of Yale in his second year to dedicate himself full-time to the project. His father, Bill Elkus, founded Clearstone Venture Partners in 1997, which invested in PayPal among other tech startups.

In a 2017 Huffington Post interview, Elkus described Helena as a new type of organization that was structurally designed for 21st century problems, and I wanted to do my part and create one.

At the Psychedelic Science 2023 fireside discussion, Helena Managing Partner Basu explained that the organisation has both a not-for-profit arm (a kind of policy arm) as well as a for-profit investment fund.

Follow this link:

MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha

Posted in Psychedelics | Comments Off on MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics – Psychedelic Alpha

Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care – Open Access Government

Posted: at 6:31 pm

The European Union stands at a critical juncture in addressing the escalating crisis of mental health disorders. With the ongoing review of EU pharmaceutical legislation, there is a pressing need to realign our healthcare innovation priorities to better address the unmet needs in mental health care.

Current data paints a concerning picture of the mental health burden in Europe. According to the OECD, half of the population will face mental illness at some point in their lives. (1) In the EU, 32 million citizens (7.2%) suffer from chronic depression, (2) a condition with a high risk of suicide. WHO Europe reports that 75% of major depression cases lack adequate treatment. (3) Up to 50% of treated patients experience treatment resistance, (4) and nearly one-third will attempt suicide. (5) Annually, 130,000 Europeans die by suicide. (6) These stark realities underscore the urgency of addressing mental health as a public health priority.

Despite the clear need, the innovation landscape in mental health care is lagging. Current estimates suggest that by 2040, we will only be able to prevent 14% of the burden arising from mental health conditions. (7) The pharmaceutical sector has seen limited progress in developing new treatments for mental health. There are approximately 30 different antidepressants, 20 antipsychotic drugs, seven mood stabilizers for bipolar disorder, and six different classes of drugs for ADHD available. Regrettably, almost none of these are more effective than the medications available three decades ago, despite some improvements in side-effect profiles. (8)

Last year, of the 89 new medicines recommended for approval by the European Medicines Agency, not a single one targeted mental health conditions. (9) Since 2015, only seven neuropsychiatric drugs have been approved globally, in stark contrast to the 80 drugs approved in the field of oncology. (10)

This innovation gap in mental health care is a significant concern. Against this backdrop, among the most promising areas in mental health innovation are novel psychedelic treatments. These therapies have shown potential in clinical trials, offering rapid and durable effects in treating various mental health conditions and substance use disorders. These therapies offer new hope for many patients, particularly those who have not found relief through conventional treatments.

The global landscape for psychedelic therapy is evolving rapidly. This year, Australia became the first country to officially regulate the medical use of psychedelics for the treatment of PTSD and depression. In the US, the first psychedelic therapy is anticipated to be approved by 2024.

Despite significant progress in this field, Europe currently faces a shortfall in late-stage programs that facilitate the approval of new treatments. Numerous early and mid-stage trials are underway within Europe, and the continent has been a fertile ground for pioneering insights in psychedelic research, largely thanks to the contributions of European scientists and study participants. Nevertheless, the majority of the regulatory support and flexibility that encourages the advancement of these treatments into their final stages of development is predominantly seen outside of Europe. This disparity poses a risk of Europe lagging in the international effort to develop and authorize these groundbreaking treatments.

The EU has previously demonstrated its ability to incentivize R&D in specific areas, such as orphan and paediatric medicines. This success can serve as a model for mental health care. By leveraging the pharmaceutical legislation review, the EU has the opportunity to foster innovation and support the development of novel mental health treatments.

To make this possible, the current EU criteria for unmet medical needs need to be expanded from merely looking at life-threatening or severely debilitating conditions to including the prevalence of conditions and their societal impact. This call was included in a recently launched European Parliament policy paper Unmet Medical Needs: Aligning Medical Innovation with Societal Health Needs authored by the Psychedelic Access and Research European Alliance (PAREA).

The paper also calls for the establishment of a European Hub for Mental Health R&D. This hub would unite EU institutions, Member States, healthcare funders, and philanthropic organizations to foster evidence-based decision-making in mental health and to set effective incentives and prioritize resources, driving innovation and addressing the substantial unmet medical needs in mental health care across Europe.

The EU is at a crossroads in mental health care. The choices made today in the realm of pharmaceutical legislation will have far-reaching implications for the future of mental health care. It is our collective responsibility to ensure that these choices pave the way for a healthier, more resilient society where mental wellbeing is not just an aspiration but a reality.

See the original post:

Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government

Posted in Psychedelics | Comments Off on Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care – Open Access Government

The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes – Austin Chronicle

Posted: at 6:31 pm

The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes  Austin Chronicle

See original here:

The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle

Posted in Psychedelics | Comments Off on The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes – Austin Chronicle

This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment – Inverse

Posted: at 6:31 pm

Ibogaine is currently among the buzziest psychedelics, promising to upend the landscape of mental health care and support. First discovered to curb addiction in the 1960s, the drug was declared an illegal substance by the 1970s. Now, ibogaine is making a comeback not only for treating addiction but anxiety, depression, and now traumatic brain injuries.

In a study published Friday in the journal Nature Medicine, military veterans with mostly mild traumatic brain injuries underwent a combination treatment of magnesium and ibogaine in Mexico, where the psychedelic is legal. One month following their treatment, the individuals reported feeling immense relief from symptoms associated with post-traumatic stress disorder (PTSD), anxiety, and depression, as well as improved cognition.

No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury, Nolan Williams, an associate professor of psychiatry and behavioral sciences at Stanford University School of Medicine, who led the study, said in a press release. The results are dramatic, and we intend to study this compound further.

Ibogaine is a naturally occurring compound found in the roots of a shrub called Tabernanthe iboga, which is native to Central Africa and has been used for centuries for ceremonial practices.

Ibogaine acts as a stimulant in small doses but is a powerful psychedelic in large doses. What it does in the brain, however, isnt well understood. Studies in rats show that ibogaine may increase proteins that encourage neuroplasticity, which could explain how it helps the brain rewire itself, overcoming seemingly hard-set neural patterns of addiction.

While ibogaine isnt legal in the U.S., that hasnt deterred a growing number of individuals from flocking to clinics in Mexico (where the substance is unregulated) seeking treatment for addiction and other mental health issues.

There were a handful of veterans who had gone to this clinic in Mexico and were reporting anecdotally that they had great improvements in all kinds of areas of their lives after taking ibogaine, Williams said. Our goal was to characterize those improvements with structured clinical and neurobiological assessments.

To do this, Williams and his colleagues at Stanford recruited 30 military veterans who had been in special operations with a history of traumatic brain injuries a condition causing other mental health issues like PTSD, depression, and anxiety and repeated blast or combat exposures. The participants first underwent neuro- and psychological evaluations at Stanford and, a few days later, traveled by themselves to the Ambio Treatment Clinic located in Tijuana, Mexico.

At the clinic, the group took an oral dose of ibogaine paired with an intravenous drip of magnesium to prevent any side effects to the heart and cardiovascular system, which the psychedelic is known to do. Participants also participated in some wellness activities while at the clinic, such as reiki, meditation, yoga, and massage. They were then re-evaluated at Stanford four to five days and one month after the ibogaine treatment.

The results were significant. The average disability score for the participants before the treatment was equivalent to mild to moderate disability. This changed to no disability on the one-month follow-up. The veterans also reported, on average, an 88 percent reduction in symptoms associated with PTSD, 87 percent for depression, and 81 percent in anxiety relative to before the ibogaine treatment. They also did much better on their cognitive tests with respect to overall concentration, information processing, memory, and impulse control.

Before the treatment, I was living life in a blizzard with zero visibility and a cold, hopeless, listless feeling, Sean, a 51-year-old veteran from Arizona with six combat deployments who participated in the study, said in the press release. After ibogaine, the storm lifted.

These findings complement other studies involving military veterans that, similarly, have found ibogaine vastly improved cognitive impairment, PTSD, anxiety, and depression.

In light of the promising research thus far, pharmaceutical companies are already gearing up to develop drugs from ibogaine. German-based atai Life Sciences made an ibogaine formulation to treat opioid-use disorder that completed an early phase clinical trial in the U.K. At the University of California, San Francisco, researchers developed an antidepressant that mimics ibogaines impact on the protein that transports the neurotransmitter serotonin.

Since this study was purely observational, Williams and his colleagues are interested in expanding their research to include brain imaging to see exactly what sort of structural changes or otherwise are going on. The researchers believe ibogaine could be a veritable game-changer not just for traumatic brain injuries but a whole laundry list of neurological and psychiatric conditions.

In addition to treating [traumatic brain injury], I think this may emerge as a broader neuro-rehab drug, Williams said. I think it targets a whole host of different brain areas and can help us better understand how to treat other forms of PTSD, anxiety, and depression that arent necessarily linked to TBI.

View post:

This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse

Posted in Psychedelics | Comments Off on This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment – Inverse

A ‘milestone’ for psychedelics: Pentagon directed to study alternative treatments for veterans – Washington Times

Posted: at 6:31 pm

A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans  Washington Times

Read the rest here:

A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times

Posted in Psychedelics | Comments Off on A ‘milestone’ for psychedelics: Pentagon directed to study alternative treatments for veterans – Washington Times

Page 21234..1020..»